{"id":"drug-cisplatin","safety":{"commonSideEffects":[{"rate":"28-36%","effect":"Nephrotoxicity"},{"rate":"25-30%","effect":"Ototoxicity"},{"rate":"76-99%","effect":"Nausea and vomiting"},{"rate":"25-35%","effect":"Myelosuppression (thrombocytopenia)"},{"rate":"25-35%","effect":"Myelosuppression (leukopenia)"},{"rate":"10-20%","effect":"Peripheral neuropathy"},{"rate":"20-25%","effect":"Anemia"},{"rate":"50-70%","effect":"Electrolyte abnormalities (hypomagnesemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific but most effective against cells in S and G2 phases.","oneSentence":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:04.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic testicular cancer"},{"name":"Metastatic ovarian cancer"},{"name":"Advanced bladder cancer"},{"name":"Head and neck cancer"},{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06492460","phase":"PHASE3","title":"2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-20","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":422},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1490,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CDDP Drug"],"phase":"phase_3","status":"active","brandName":"Drug：Cisplatin","genericName":"Drug：Cisplatin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}